Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease

NCT06531395 is registered in ClinicalTrials.gov with Kiniksa Pharmaceuticals International, plc as lead sponsor.

NCT NCT06531395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06531395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Phase
Phase 2
Overall status
Terminated
Start date
July 17, 2024
Completion date
May 1, 2025
Enrollment
3 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

sjögrens disease